What is the recommended management for a patient with chronic persistent allergic rhinitis whose symptoms interfere with daily activities?

Management of Chronic Allergic Rhinitis

Intranasal corticosteroids are the first-line treatment for chronic persistent allergic rhinitis when symptoms interfere with daily activities, and should be used continuously on a daily basis—not intermittently or "as needed." 1

Initial Treatment Approach

Primary Therapy: Intranasal Corticosteroids

• Start with intranasal corticosteroids (fluticasone propionate, mometasone furoate, budesonide, or triamcinolone acetonide) as monotherapy for all patients with moderate-to-severe symptoms affecting quality of life. 1, 2
• All approved intranasal corticosteroids provide comparable efficacy; differences relate only to potency, dosing schedule, and patient preference. 2, 3
• Intranasal corticosteroids control all nasal symptoms—congestion, rhinorrhea, sneezing, and itching—and are superior to oral antihistamines, leukotriene receptor antagonists, and other medication classes. 2, 4
• Instruct patients to direct the spray away from the nasal septum to maximize mucosal contact, minimize local irritation, and reduce risk of epistaxis. 2, 4
• Continue daily use for at least 2-4 weeks before assessing response; intranasal corticosteroids require continuous daily administration to achieve optimal efficacy. 4, 5

Alternative First-Line for Mild Symptoms

• For patients with mild intermittent symptoms where sneezing and itching predominate (rather than congestion), oral second-generation antihistamines (loratadine, cetirizine, fexofenadine) may be used as initial monotherapy. 1
• However, oral antihistamines have limited effect on nasal congestion and are significantly less effective than intranasal corticosteroids for overall symptom control. 4, 6

Escalation for Inadequate Response to Monotherapy

Add Intranasal Antihistamine

• If symptoms persist after 2-4 weeks of daily intranasal corticosteroid use, add an intranasal antihistamine (azelastine or olopatadine) to the regimen. 1, 2
• The combination of intranasal corticosteroid plus intranasal antihistamine provides 37.9% symptom reduction compared to 29.1% with intranasal corticosteroid alone—superior to either agent as monotherapy. 2, 4, 7, 6
• This combination is strongly recommended for moderate-to-severe allergic rhinitis based on high-quality evidence. 2
• Do NOT add an oral antihistamine to intranasal corticosteroids; this combination provides no additional benefit. 2

Symptom-Specific Add-On Therapies

• For predominant watery rhinorrhea: Add intranasal ipratropium bromide (0.03%, 42 µg per nostril 2-3 times daily), which specifically reduces nasal discharge without affecting other symptoms. 1, 8, 2
• The combination of ipratropium bromide with intranasal corticosteroids is more effective than either alone without increasing adverse effects. 8, 2, 4
• For concomitant asthma: Consider adding montelukast 10 mg once daily, though it is less effective than intranasal corticosteroids and should not be used as primary therapy. 1, 2, 9

Assessment of Comorbidities

• Evaluate and document the presence of associated conditions: asthma, atopic dermatitis, sleep-disordered breathing, conjunctivitis, rhinosinusitis, and otitis media. 1
• These comorbidities may require concurrent management and influence treatment decisions. 1

Allergy Testing and Environmental Control

• Perform or refer for specific IgE testing (skin or blood) when patients do not respond to empiric treatment, when diagnosis is uncertain, or when knowledge of specific allergens is needed to target therapy. 1
• Advise avoidance of identified allergens and environmental controls (removal of pets, air filtration systems, bed covers, acaricides for dust mites) when specific allergens correlate with clinical symptoms. 1
• Nasal saline irrigation (isotonic or hypertonic) is beneficial as sole therapy or adjunctive treatment for chronic rhinorrhea. 8, 2

Management of Refractory Disease

Immunotherapy Referral

• Refer patients to an allergist for immunotherapy (subcutaneous or sublingual) when symptoms remain inadequate despite optimal pharmacologic therapy with intranasal corticosteroids plus intranasal antihistamine. 1, 2, 4
• Immunotherapy is the only disease-modifying treatment for allergic rhinitis and can prevent development of new allergen sensitizations and reduce future asthma risk. 2, 7, 6

Short-Course Oral Corticosteroids (Use Sparingly)

• Reserve oral prednisone (0.5-1 mg/kg/day, maximum 60 mg, for 5-7 days) only for very severe or intractable symptoms that markedly impair quality of life after all other pharmacologic options have failed. 1, 8, 2
• Oral corticosteroids carry substantially higher risks of systemic adverse effects including adrenal suppression, hyperglycemia, mood changes, and bone-density loss. 2

Surgical Options

• Consider referral for inferior turbinate reduction in patients with nasal airway obstruction and enlarged inferior turbinates who have failed medical management. 1
• Acupuncture may be offered for patients interested in nonpharmacologic therapy. 1

Critical Pitfalls to Avoid

• Never use intranasal corticosteroids intermittently or "as needed"—they must be used daily for optimal efficacy. 4, 5
• Do not use topical nasal decongestants for more than 3 consecutive days due to risk of rhinitis medicamentosa (rebound congestion). 1, 8, 2, 4
• Never administer intramuscular or depot corticosteroids—they are contraindicated due to risk of serious systemic side effects including adrenal suppression and tissue atrophy. 1, 2, 4
• Do not offer oral leukotriene receptor antagonists as primary therapy; they are significantly less effective than intranasal corticosteroids. 1, 2
• Do not routinely perform sinonasal imaging in patients with symptoms consistent with allergic rhinitis. 1, 2
• Use oral decongestants (pseudoephedrine) with caution in patients with hypertension, cardiac arrhythmias, insomnia, prostatic enlargement, or glaucoma. 1, 8, 2

Safety and Monitoring

• Adverse effects of intranasal corticosteroids are typically mild and limited to the nasal mucosa: dryness, burning, stinging, sneezing, headache, and epistaxis occur in 5-10% of patients. 2, 3
• Systemic effects such as hypothalamic-pituitary-adrenal axis suppression or growth inhibition are not observed at recommended doses. 2
• Perform periodic nasal examination (every 6-12 months) to detect mucosal erosions that could precede rare septal perforations. 8
• Cetirizine and intranasal azelastine may cause sedation at recommended doses; other second-generation antihistamines are generally non-sedating. 2